Thanks. You're right ARWR is not ABUS. ABUS is trading less than cash (by a good margin). But ARWR is roughly a year ahead in the clinic, and in this market, about all you'll get from that is a 2x premium. They may have a bit more than 80 mill, so let's say they have 90. 2x90=180, putting the SP right around 3.
You may be a good swing trader wyattkap, but "10X's upside over the next several quarters" is so far from the realm of possibility that it's laughable, and I've read your posts for awhile, you usually don't make such absurd predictions. The market isn't ready to recover, it's still in a severe downtrend and biotechs are the least likely to recover quickly. Even with great news from the Monarch study this summer, at the very best, you might see a doubling from here--maybe.